- Records
- 19
- Recruiting
- 11
- Recruiting sites
- 613
- Countries
- 18
ClinicalTrials.gov registry snapshot / 2026-07-24Peptide trials,
Peptide trials,
without the maze.
Search every official registry record matched to 13 tracked peptide and next-generation weight-loss programs. Find current status, phase, enrollment, countries, US states, recruiting cities, postal areas, completion timing, and the direct NCT source.
268unique NCT records
13named programs
53countries represented
1,840recruiting cities
11registry result modules
Recruiting footprint by program
Study status is not drug rank.
Bar length shows registry-listed sites individually marked Recruiting. Larger programs can create larger counts. This does not compare efficacy, safety, approval odds, sponsor quality, or enrollment availability.
- Records
- 52
- Recruiting
- 10
- Recruiting sites
- 170
- Countries
- 7
- Records
- 37
- Recruiting
- 10
- Recruiting sites
- 73
- Countries
- 3
- Records
- 24
- Recruiting
- 10
- Recruiting sites
- 935
- Countries
- 28
- Records
- 27
- Recruiting
- 6
- Recruiting sites
- 1,581
- Countries
- 36
- Records
- 30
- Recruiting
- 5
- Recruiting sites
- 155
- Countries
- 6
- Records
- 8
- Recruiting
- 4
- Recruiting sites
- 339
- Countries
- 23
- Records
- 31
- Recruiting
- 3
- Recruiting sites
- 774
- Countries
- 34
- Records
- 15
- Recruiting
- 3
- Recruiting sites
- 3
- Countries
- 1
- Records
- 34
- Recruiting
- 2
- Recruiting sites
- 450
- Countries
- 27
- Records
- 9
- Recruiting
- 2
- Recruiting sites
- 4
- Countries
- 3
- Records
- 9
- Recruiting
- 1
- Recruiting sites
- 8
- Countries
- 1
- Records
- 5
- Recruiting
- 0
- Recruiting sites
- 0
- Countries
- 0
Official registry finder
Filter the exact records.
Search names, former codes, NCT IDs, sponsors, interventions, conditions, cities, and postal codes. Filtered URLs are shareable but intentionally excluded from search indexing so this page remains the canonical source.
149matching registry records
Matching recruiting site observations1,481
| Program and record | Status | Phase and enrollment | Locations | Primary completion | Registry update | Source |
|---|---|---|---|---|---|---|
| AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose WeightNCT07339423 / AMAZE 1 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 31,150 estimated | 22 matching recruitingMiramar, Florida, 33027, United States / Orlando, Florida, 32801, United States / Conyers, Georgia, 30094, United States / 19 more areas | Jun 26, 2029estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT07339423 ↗ |
| A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainNCT07481630 / AMAZE 5 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3400 estimated | 19 matching recruitingPhoenix, Arizona, 85053, United States / Walnut Creek, California, 94598, United States / Hamden, Connecticut, 06517, United States / 16 more areas | Aug 14, 2028estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT07481630 ↗ |
| AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight LossNCT07503210 / AMAZE 12 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3600 estimated | 12 matching recruitingAnniston, Alabama, 36207, United States / Walnut Creek, California, 94598, United States / Orlando, Florida, 32825, United States / 9 more areas | Jun 6, 2028estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT07503210 ↗ |
| AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce PainNCT07509307 / AMAZE 6 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3400 estimated | 17 matching recruitingEscondido, California, 92025, United States / Lancaster, California, 93534, United States / Palm Springs, California, 92262, United States / 14 more areas | Aug 14, 2028estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT07509307 ↗ |
| AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightNCT07533175 / AMAZE 2 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3630 estimated | 15 matching recruitingBirmingham, Alabama, 35294, United States / Escondido, California, 92025, United States / Lomita, California, 90717, United States / 12 more areas | Aug 7, 2028estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT07533175 ↗ |
| A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and ObesityNCT07567001 / HF-POLARIS / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 35,610 estimated | 118 matching recruitingAlexander City, Alabama, 35010, United States / Fairhope, Alabama, 36532, United States / Glendale, Arizona, 85304, United States / 114 more areas | Jul 23, 2029estimated | Jul 15, 2026ClinicalTrials.gov | Open NCT07567001 ↗ |
| AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaNCT07571005 / AMAZE 3 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3300 estimated | 15 matching recruitingSan Diego, California, 92123, United States / Miami, Florida, 33176, United States / Ocala, Florida, 34470, United States / 11 more areas | Jul 12, 2028estimated | Jul 13, 2026ClinicalTrials.gov | Open NCT07571005 ↗ |
| AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaNCT07571109 / AMAZE 4 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3300 estimated | 19 matching recruitingGilbert, Arizona, 85297, United States / Bradenton, Florida, 34209, United States / Naples, Florida, 34102, United States / 15 more areas | Jun 26, 2028estimated | Jul 13, 2026ClinicalTrials.gov | Open NCT07571109 ↗ |
| A Study on How NNC0174-1213 Works in People With Overweight or Obesity.NCT06719011 / Novo Nordisk A/S | RecruitingVerified 2025-05 | Phase 1177 estimated | 2 matching recruitingSan Antonio, Texas, 78209, United States / Salt Lake City, Utah, 84124, United States | Mar 26, 2026estimated | May 25, 2025ClinicalTrials.gov | Open NCT06719011 ↗ |
| A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to DietNCT07184086 / Novo Nordisk A/S | RecruitingVerified 2025-10 | Phase 180 estimated | 2 matching recruitingOrlando, Florida, 32804, United States / Baton Rouge, Louisiana, 70808-4124, United States | Oct 12, 2027estimated | Oct 8, 2025ClinicalTrials.gov | Open NCT07184086 ↗ |
| A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body WeightNCT07253285 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 3460 estimated | 10 matching recruitingHollywood, Florida, 33024, United States / Weston, Florida, 33331, United States / Atlanta, Georgia, 30329, United States / 7 more areas | Mar 20, 2030estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07253285 ↗ |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414 / Novo Nordisk A/S | RecruitingVerified 2026-07 | Phase 32,500 estimated | 94 matching recruitingBirmingham, Alabama, 35294, United States / Pelham, Alabama, 35124, United States / Gilbert, Arizona, 85296, United States / 87 more areas | Feb 23, 2028estimated | Jul 8, 2026ClinicalTrials.gov | Open NCT07564414 ↗ |
| Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse EventsNCT07607587 / Novo Nordisk A/S | RecruitingVerified 2026-06 | Phase 1114 estimated | 10 matching recruitingWalnut Creek, California, 94598, United States / Fleming Island, Florida, 32003, United States / Jacksonville, Florida, 32216, United States / 7 more areas | Nov 19, 2027estimated | Jun 25, 2026ClinicalTrials.gov | Open NCT07607587 ↗ |
| A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightNCT06143956 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 21,481 estimated | 43 matching recruitingChandler, Arizona, 85225, United States / Scottsdale, Arizona, 85260, United States / Tucson, Arizona, 85712, United States / 40 more areas | Sep 2027estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT06143956 ↗ |
| A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 DiabetesNCT07215559 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 2200 estimated | 26 matching recruitingGilbert, Arizona, 85296, United States / Phoenix, Arizona, 85020, United States / Tucson, Arizona, 85741, United States / 23 more areas | Mar 2027estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07215559 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 DiabetesNCT07282600 / ENLIGHTEN-2 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 31,035 estimated | 60 matching recruitingBirmingham, Alabama, 35209, United States / Cullman, Alabama, 35055, United States / Tucson, Arizona, 85712, United States / 57 more areas | Jan 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07282600 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesNCT07321886 / ENLIGHTEN-1 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 31,980 estimated | 41 matching recruitingTuscaloosa, Alabama, 35405, United States / Scottsdale, Arizona, 85260, United States / Escondido, California, 92025, United States / 38 more areas | Mar 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07321886 ↗ |
| Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or OverweightNCT07353931 / ENLIGHTEN-4 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 3900 estimated | 34 matching recruitingMobile, Alabama, 36608, United States / Mesa, Arizona, 85206, United States / Mesa, Arizona, 85209, United States / 31 more areas | Mar 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07353931 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or OverweightNCT07369011 / ENLIGHTEN-3 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 3800 estimated | 23 matching recruitingCullman, Alabama, 35055, United States / Long Beach, California, 90815, United States / Los Alamitos, California, 90720, United States / 20 more areas | Mar 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07369011 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinNCT07392190 / ENLIGHTEN-6 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 3900 estimated | 51 matching recruitingBirmingham, Alabama, 35209, United States / Phoenix, Arizona, 85016, United States / Scottsdale, Arizona, 85260, United States / 48 more areas | Jun 2028estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07392190 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers.NCT07401862 / Eli Lilly and Company | RecruitingVerified 2026-06 | Phase 136 estimated | 2 matching recruitingOrlando, Florida, 32809, United States / San Antonio, Texas, 78215, United States | Mar 2027estimated | Jun 4, 2026ClinicalTrials.gov | Open NCT07401862 ↗ |
| A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal FunctionNCT07426380 / Eli Lilly and Company | RecruitingVerified 2026-03 | Phase 128 estimated | 2 matching recruitingMiami Lakes, Florida, 33016-1518, United States / Orlando, Florida, 32808, United States | Oct 2026estimated | Mar 13, 2026ClinicalTrials.gov | Open NCT07426380 ↗ |
| A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or OverweightNCT07589608 / Eli Lilly and Company | RecruitingVerified 2026-06 | Phase 2400 estimated | 40 matching recruitingChandler, Arizona, 85225, United States / Scottsdale, Arizona, 85260, United States / Tucson, Arizona, 85712, United States / 37 more areas | Sep 2027estimated | Jun 24, 2026ClinicalTrials.gov | Open NCT07589608 ↗ |
| A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 DiabetesNCT07351045 / Enith1 / Hoffmann-La Roche | RecruitingVerified 2026-07 | Phase 32,000 estimated | 36 matching recruitingAnniston, Alabama, 36207, United States / Birmingham, Alabama, 35235, United States / Birmingham, Alabama, 35294-3360, United States / 33 more areas | Jul 24, 2028estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT07351045 ↗ |
| A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 DiabetesNCT07351058 / Enith2 / Hoffmann-La Roche | RecruitingVerified 2026-07 | Phase 31,600 estimated | 35 matching recruitingGuntersville, Alabama, 35976, United States / Tucson, Arizona, 85711, United States / Lake Forest, California, 92630, United States / 32 more areas | Aug 7, 2028estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT07351058 ↗ |
| Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or ObesityNCT07037433 / MARITIME-CV / Amgen | RecruitingVerified 2026-07 | Phase 312,800 estimated | 138 matching recruitingDaphne, Alabama, 36526, United States / Fairhope, Alabama, 36532, United States / Huntsville, Alabama, 35801, United States / 134 more areas | Jun 30, 2028estimated | Jul 24, 2026ClinicalTrials.gov | Open NCT07037433 ↗ |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and ObesityNCT07037459 / MARITIME-HF / Amgen | RecruitingVerified 2026-06 | Phase 35,056 estimated | 110 matching recruitingBirmingham, Alabama, 35205, United States / Dothan, Alabama, 36305, United States / Fairhope, Alabama, 36532, United States / 105 more areas | Jun 30, 2028estimated | Jul 2, 2026ClinicalTrials.gov | Open NCT07037459 ↗ |
| Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure TherapyNCT07225686 / MARITIME-OSA-1 / Amgen | RecruitingVerified 2026-06 | Phase 3250 estimated | 13 matching recruitingNorthridge, California, 91325, United States / Rolling Hills Estates, California, 90274, United States / Brandon, Florida, 33511, United States / 10 more areas | Sep 29, 2027estimated | Jun 12, 2026ClinicalTrials.gov | Open NCT07225686 ↗ |
| Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) TherapyNCT07226765 / MARITIME-OSA-2 / Amgen | RecruitingVerified 2026-06 | Phase 3250 estimated | 13 matching recruitingNorthridge, California, 91325, United States / Rolling Hills Estates, California, 90274, United States / Brandon, Florida, 33511, United States / 10 more areas | Sep 29, 2027estimated | Jun 12, 2026ClinicalTrials.gov | Open NCT07226765 ↗ |
| A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or OverweightNCT07441252 / Amgen | RecruitingVerified 2026-06 | Phase 2180 estimated | 23 matching recruitingChandler, Arizona, 85224, United States / Phoenix, Arizona, 85044, United States / Tucson, Arizona, 85715, United States / 18 more areas | Sep 29, 2027estimated | Jun 18, 2026ClinicalTrials.gov | Open NCT07441252 ↗ |
| Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)NCT07575399 / Amgen | RecruitingVerified 2026-07 | Phase 3300 estimated | 43 matching recruitingPelham, Alabama, 35124, United States / Chandler, Arizona, 85224, United States / Sun City, Arizona, 85351, United States / 40 more areas | Jan 3, 2028estimated | Jul 23, 2026ClinicalTrials.gov | Open NCT07575399 ↗ |
| RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)NCT07009860 / Altimmune, Inc. | RecruitingVerified 2026-03 | Phase 2100 estimated | 8 matching recruitingNorth Little Rock, Arkansas, 72117, United States / Doral, Florida, 33122, United States / Miami, Florida, 33125, United States / 5 more areas | Mar 31, 2027estimated | Mar 20, 2026ClinicalTrials.gov | Open NCT07009860 ↗ |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)NCT07165028 / Eli Lilly and Company | RecruitingVerified 2026-07 | Phase 34,500 estimated | 134 matching recruitingTuscaloosa, Alabama, 35405, United States / Chandler, Arizona, 85224, United States / Gilbert, Arizona, 85297, United States / 129 more areas | Aug 2030estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT07165028 ↗ |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisNCT06632444 / Boehringer Ingelheim | RecruitingVerified 2026-07 | Phase 31,800 estimated | 143 matching recruitingPeoria, Arizona, 85381, United States / Scottsdale, Arizona, 85258, United States / Tucson, Arizona, 85712, United States / 135 more areas | Dec 27, 2031estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT06632444 ↗ |
| LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisNCT06632457 / Boehringer Ingelheim | RecruitingVerified 2026-07 | Phase 31,590 estimated | 108 matching recruitingPeoria, Arizona, 85381, United States / Scottsdale, Arizona, 85258, United States / Tucson, Arizona, 85712, United States / 103 more areas | Jun 5, 2029estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT06632457 ↗ |
| AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose WeightNCT07400107 / AMAZE 8 / Novo Nordisk A/S | Not yet recruitingVerified 2026-03 | Phase 31,000 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Dec 12, 2028estimated | Mar 12, 2026ClinicalTrials.gov | Open NCT07400107 ↗ |
| A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to SemaglutideNCT07668414 / AMAZE 7 / Novo Nordisk A/S | Not yet recruitingVerified 2026-06 | Phase 3650 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Oct 10, 2028estimated | Jun 25, 2026ClinicalTrials.gov | Open NCT07668414 ↗ |
| AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose WeightNCT07720271 / AMAZE 9 / Novo Nordisk A/S | Not yet recruitingVerified 2026-07 | Phase 3950 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 27, 2028estimated | Jul 22, 2026ClinicalTrials.gov | Open NCT07720271 ↗ |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 DiabetesNCT07282613 / REIMAGINEYOUNG / Novo Nordisk A/S | Not yet recruitingVerified 2026-05 | Phase 380 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 7, 2029estimated | May 28, 2026ClinicalTrials.gov | Open NCT07282613 ↗ |
| A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesNCT07553299 / Verdiva Bio Dev Limited | Not yet recruitingVerified 2026-06 | Phase 2120 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 30, 2026estimated | Jun 3, 2026ClinicalTrials.gov | Open NCT07553299 ↗ |
| A Study of Eloralintide (LY3841136) in Healthy ParticipantsNCT07701083 / Eli Lilly and Company | Not yet recruitingVerified 2026-07 | Phase 158 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Oct 2026estimated | Jul 14, 2026ClinicalTrials.gov | Open NCT07701083 ↗ |
| A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose WeightNCT05567796 / REDEFINE 1 / Novo Nordisk A/S | Active, not recruitingVerified 2026-07 | Phase 33,400 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Oct 30, 2024actual | Jul 17, 2026ClinicalTrials.gov | Open NCT05567796 ↗ |
| REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsNCT05669755 / REDEFINE 3 / Novo Nordisk A/S | Active, not recruitingVerified 2026-07 | Phase 37,101 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 1, 2027estimated | Jul 17, 2026ClinicalTrials.gov | Open NCT05669755 ↗ |
| A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With ObesityNCT06780449 / Novo Nordisk A/S | Active, not recruitingVerified 2026-01 | Phase 3400 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Aug 28, 2028estimated | Jan 20, 2026ClinicalTrials.gov | Open NCT06780449 ↗ |
| A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral NeuropathyNCT06797869 / Novo Nordisk A/S | Active, not recruitingVerified 2025-12 | Phase 2142 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Aug 21, 2026estimated | Dec 5, 2025ClinicalTrials.gov | Open NCT06797869 ↗ |
| A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termNCT07011667 / Novo Nordisk A/S | Active, not recruitingVerified 2026-07 | Phase 3609 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 1, 2027estimated | Jul 24, 2026ClinicalTrials.gov | Open NCT07011667 ↗ |
| Weight Loss in People Living With Overweight or Obesity Following Treatment With CagrilintideNCT07220642 / RENEW 1 / Novo Nordisk A/S | Active, not recruitingVerified 2026-06 | Phase 3300 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | May 11, 2027estimated | Jun 30, 2026ClinicalTrials.gov | Open NCT07220642 ↗ |
| Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintideNCT07220759 / RENEW 2 / Novo Nordisk A/S | Active, not recruitingVerified 2026-04 | Phase 3330 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | May 12, 2027estimated | Apr 21, 2026ClinicalTrials.gov | Open NCT07220759 ↗ |
| A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body WeightNCT07605052 / Novo Nordisk A/S | Active, not recruitingVerified 2026-07 | Phase 150 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 3, 2026estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT07605052 ↗ |
| A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related ComorbiditiesNCT07281937 / EVOLVE-2 / Verdiva Bio Dev Limited | Active, not recruitingVerified 2026-06 | Phase 2206 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 2026estimated | Jun 3, 2026ClinicalTrials.gov | Open NCT07281937 ↗ |
| A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 DiabetesNCT06603571 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 2367 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 1, 2026actual | Jul 17, 2026ClinicalTrials.gov | Open NCT06603571 ↗ |
| A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes MellitusNCT06628362 / Carmot Therapeutics, Inc. | Active, not recruitingVerified 2026-06 | Phase 2447 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | May 29, 2026actual | Jun 24, 2026ClinicalTrials.gov | Open NCT06628362 ↗ |
| A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)NCT06660173 / Amgen | Active, not recruitingVerified 2025-11 | Phase 2409 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Oct 6, 2025actual | Nov 25, 2025ClinicalTrials.gov | Open NCT06660173 ↗ |
| Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858839 / MARITIME-1 / Amgen | Active, not recruitingVerified 2025-10 | Phase 33,853 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jan 21, 2027estimated | Oct 20, 2025ClinicalTrials.gov | Open NCT06858839 ↗ |
| Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are OverweightNCT06858878 / MARITIME-2 / Amgen | Active, not recruitingVerified 2025-12 | Phase 31,105 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jan 21, 2027estimated | Dec 31, 2025ClinicalTrials.gov | Open NCT06858878 ↗ |
| A Study to Evaluate the Effect of Maridebart Cafraglutide on Insulin Sensitivity and β-cell Function in Participants With Type 2 Diabetes MellitusNCT07160257 / Amgen | Active, not recruitingVerified 2026-06 | Phase 156 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 15, 2026estimated | Jun 12, 2026ClinicalTrials.gov | Open NCT07160257 ↗ |
| Effect of Maridebart Cafraglutide on the Heart's Electrical ActivityNCT07229157 / Amgen | Active, not recruitingVerified 2026-01 | Phase 181 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Aug 26, 2026estimated | Jan 23, 2026ClinicalTrials.gov | Open NCT07229157 ↗ |
| Effect of Maridebart Cafraglutide on How Oral Contraceptives Are Absorbed and Processed in the Body in Postmenopausal Female Participants Living With Overweight or ObesityNCT07523711 / Amgen | Active, not recruitingVerified 2026-07 | Phase 149 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 18, 2026estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT07523711 ↗ |
| RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or OverweightNCT06987513 / Altimmune, Inc. | Active, not recruitingVerified 2025-11 | Phase 2100 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | May 2026estimated | Nov 19, 2025ClinicalTrials.gov | Open NCT06987513 ↗ |
| Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)NCT06926842 / Zealand Pharma | Active, not recruitingVerified 2026-01 | Phase 2221 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Aug 13, 2026estimated | Jan 15, 2026ClinicalTrials.gov | Open NCT06926842 ↗ |
| A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular DiseaseNCT05882045 / TRIUMPH-3 / Eli Lilly and Company | Active, not recruitingVerified 2026-05 | Phase 31,946 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Apr 16, 2026actual | May 22, 2026ClinicalTrials.gov | Open NCT05882045 ↗ |
| A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or OverweightNCT05929079 / TRIUMPH-2 / Eli Lilly and Company | Active, not recruitingVerified 2026-04 | Phase 31,000 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | May 2026estimated | Apr 13, 2026ClinicalTrials.gov | Open NCT05929079 ↗ |
| Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)NCT06260722 / Eli Lilly and Company | Active, not recruitingVerified 2026-04 | Phase 31,250 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Aug 2026estimated | Apr 13, 2026ClinicalTrials.gov | Open NCT06260722 ↗ |
| Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)NCT06297603 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 3320 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Oct 2026estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT06297603 ↗ |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)NCT06383390 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 310,000 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Feb 2029estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT06383390 ↗ |
| A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have ObesityNCT06662383 / TRIUMPH-5 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 3800 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 2026estimated | Jul 20, 2026ClinicalTrials.gov | Open NCT06662383 ↗ |
| A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With ObesityNCT06859268 / TRIUMPH-6 / Eli Lilly and Company | Active, not recruitingVerified 2026-02 | Phase 3643 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Apr 2028estimated | Mar 3, 2026ClinicalTrials.gov | Open NCT06859268 ↗ |
| A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back PainNCT07035093 / TRIUMPH-7 / Eli Lilly and Company | Active, not recruitingVerified 2026-07 | Phase 3586 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 2027estimated | Jul 23, 2026ClinicalTrials.gov | Open NCT07035093 ↗ |
| A Study of Retatrutide (LY3437943) in Participants With Obesity or OverweightNCT07232719 / TRIUMPH-8 / Eli Lilly and Company | Active, not recruitingVerified 2026-04 | Phase 3250 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 2027estimated | Apr 17, 2026ClinicalTrials.gov | Open NCT07232719 ↗ |
| A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or OverweightNCT07357415 / TRIUMPH-9 / Eli Lilly and Company | Active, not recruitingVerified 2026-06 | Phase 3600 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Oct 2028estimated | Jun 9, 2026ClinicalTrials.gov | Open NCT07357415 ↗ |
| A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With ObesityNCT06745284 / Boehringer Ingelheim | Active, not recruitingVerified 2026-05 | Phase 164 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jan 8, 2027estimated | May 12, 2026ClinicalTrials.gov | Open NCT06745284 ↗ |
| VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)NCT07104383 / Viking Therapeutics, Inc. | Active, not recruitingVerified 2026-04 | Phase 31,100 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 1, 2027estimated | Apr 7, 2026ClinicalTrials.gov | Open NCT07104383 ↗ |
| VK2735 for Weight Management Phase 3NCT07104500 / VANQUISH 1 / Viking Therapeutics, Inc. | Active, not recruitingVerified 2025-11 | Phase 34,500 estimated | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 1, 2027estimated | Nov 24, 2025ClinicalTrials.gov | Open NCT07104500 ↗ |
| A Research Study on How NNC0487-0111 Works in People With Overweight or ObesityNCT05369390 / Novo Nordisk A/S | CompletedVerified 2025-06 | Phase 1144 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jan 9, 2024actual | Jun 15, 2025ClinicalTrials.gov | Open NCT05369390 ↗ |
| A Research Study to See How a New Medicine (NNC0487-0111) Works in People With Overweight or Obesity When Injected Under the SkinNCT06064006 / Novo Nordisk A/S | CompletedVerified 2025-11 | Phase 2125 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 27, 2024actual | Nov 19, 2025ClinicalTrials.gov | Open NCT06064006 ↗ |
| A Research Study Looking at Different Oral Formulations and the Effect of Food Intake on How the Medicine NNC0487-0111 Behaves in the Body of Participants Living With Overweight or ObesityNCT06478563 / Novo Nordisk A/S | CompletedVerified 2025-08 | Phase 1133 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 5, 2025actual | Aug 11, 2025ClinicalTrials.gov | Open NCT06478563 ↗ |
| A Research Study Comparing How Well Different Doses of the Medicine NNC0487-0111 Lower Blood Sugar in People With Type 2 DiabetesNCT06542874 / Novo Nordisk A/S | CompletedVerified 2025-12 | Phase 2448 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Oct 1, 2025actual | Dec 29, 2025ClinicalTrials.gov | Open NCT06542874 ↗ |
| Investigation on Safety, Tolerability and Pharmacokinetics of Single Doses of NNC0174-0833 in Normal Weight, Overweight to Obese But Otherwise Healthy Male SubjectsNCT02300844 / Novo Nordisk A/S | CompletedVerified 2018-01 | Phase 154 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 21, 2016actual | Jan 24, 2018ClinicalTrials.gov | Open NCT02300844 ↗ |
| Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of NNC0174-0833 in Subjects With Obesity or OverweightNCT02958085 / Novo Nordisk A/S | CompletedVerified 2018-01 | Phase 196 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jan 24, 2018actual | Feb 1, 2018ClinicalTrials.gov | Open NCT02958085 ↗ |
| A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or ObeseNCT03600480 / Novo Nordisk A/S | CompletedVerified 2021-11 | Phase 196 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 12, 2020actual | Nov 17, 2021ClinicalTrials.gov | Open NCT03600480 ↗ |
| First Research Study of the Possible New Medicine NNC0113-2023 in Healthy Men.NCT03617081 / Novo Nordisk A/S | CompletedVerified 2020-01 | Phase 140 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Dec 13, 2018actual | Jan 10, 2020ClinicalTrials.gov | Open NCT03617081 ↗ |
| A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With ObesityNCT03787225 / Novo Nordisk A/S | CompletedVerified 2019-06 | Phase 166 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 4, 2019actual | Jun 24, 2019ClinicalTrials.gov | Open NCT03787225 ↗ |
| Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.NCT03856047 / Novo Nordisk A/S | CompletedVerified 2024-07Registry results posted | Phase 2706 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 2, 2020actual | Jul 5, 2024ClinicalTrials.gov | Open NCT03856047 ↗ |
| A Research Study Looking Into Blood Levels of NNC0174-0833 in People With Normal and Impaired Kidney FunctionNCT04209049 / Novo Nordisk A/S | CompletedVerified 2021-01 | Phase 133 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jan 5, 2021actual | Jan 26, 2021ClinicalTrials.gov | Open NCT04209049 ↗ |
| Research Study to Look at How Well Cagrilintide Together With Semaglutide Works in People With Type 2 DiabetesNCT04982575 / Novo Nordisk A/S | CompletedVerified 2025-12Registry results posted | Phase 292 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 7, 2022actual | Dec 23, 2025ClinicalTrials.gov | Open NCT04982575 ↗ |
| Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)NCT05016882 / Novo Nordisk A/S | CompletedVerified 2025-11 | Phase 2698 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Dec 17, 2024actual | Nov 19, 2025ClinicalTrials.gov | Open NCT05016882 ↗ |
| A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose WeightNCT05394519 / REDEFINE 2 / Novo Nordisk A/S | CompletedVerified 2026-01 | Phase 31,200 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jan 28, 2025actual | Jan 28, 2026ClinicalTrials.gov | Open NCT05394519 ↗ |
| A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06065540 / REIMAGINE 2 / Novo Nordisk A/S | CompletedVerified 2026-07 | Phase 32,734 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 19, 2025actual | Jul 8, 2026ClinicalTrials.gov | Open NCT06065540 ↗ |
| A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and PlaceboNCT06131372 / Novo Nordisk A/S | CompletedVerified 2026-03 | Phase 2626 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 24, 2025actual | Apr 1, 2026ClinicalTrials.gov | Open NCT06131372 ↗ |
| A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose WeightNCT06131437 / Novo Nordisk A/S | CompletedVerified 2026-02 | Phase 3809 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Dec 8, 2025actual | Feb 6, 2026ClinicalTrials.gov | Open NCT06131437 ↗ |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 InhibitorNCT06221969 / Novo Nordisk A/S | CompletedVerified 2026-04 | Phase 31,024 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 4, 2026actual | Apr 22, 2026ClinicalTrials.gov | Open NCT06221969 ↗ |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without MetforminNCT06323161 / REIMAGINE 3 / Novo Nordisk A/S | CompletedVerified 2025-11 | Phase 3274 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 9, 2025actual | Nov 28, 2025ClinicalTrials.gov | Open NCT06323161 ↗ |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and ExerciseNCT06323174 / REIMAGINE 1 / Novo Nordisk A/S | CompletedVerified 2026-03 | Phase 3189 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Oct 1, 2025actual | Apr 2, 2026ClinicalTrials.gov | Open NCT06323174 ↗ |
| A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose WeightNCT06388187 / Novo Nordisk A/S | CompletedVerified 2026-05 | Phase 3300 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Apr 22, 2026actual | May 5, 2026ClinicalTrials.gov | Open NCT06388187 ↗ |
| Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseaseNCT06409130 / Novo Nordisk A/S | CompletedVerified 2026-03 | Phase 2270 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 21, 2025actual | Mar 12, 2026ClinicalTrials.gov | Open NCT06409130 ↗ |
| A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or BothNCT06534411 / REIMAGINE 5 / Novo Nordisk A/S | CompletedVerified 2026-07 | Phase 31,023 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 2, 2026actual | Jul 17, 2026ClinicalTrials.gov | Open NCT06534411 ↗ |
| A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or ObesityNCT06716307 / Novo Nordisk A/S | CompletedVerified 2025-08 | Phase 118 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 28, 2025actual | Aug 27, 2025ClinicalTrials.gov | Open NCT06716307 ↗ |
| A Study of LY3841136 in Healthy and Overweight ParticipantsNCT05295940 / Eli Lilly and Company | CompletedVerified 2024-03 | Phase 1148 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jan 25, 2024actual | Apr 1, 2024ClinicalTrials.gov | Open NCT05295940 ↗ |
| A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or OverweightNCT06230523 / Eli Lilly and Company | CompletedVerified 2026-05Registry results posted | Phase 2263 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | May 30, 2025actual | Jun 24, 2026ClinicalTrials.gov | Open NCT06230523 ↗ |
| A Study of LY3841136 in Overweight and Obese ParticipantsNCT06345066 / Eli Lilly and Company | CompletedVerified 2025-10 | Phase 196 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 29, 2025actual | Oct 15, 2025ClinicalTrials.gov | Open NCT06345066 ↗ |
| A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or ObesityNCT06916065 / Eli Lilly and Company | CompletedVerified 2026-01 | Phase 1188 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jan 19, 2026actual | Jan 30, 2026ClinicalTrials.gov | Open NCT06916065 ↗ |
| A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related ComorbidityNCT06525935 / Carmot Therapeutics, Inc. | CompletedVerified 2026-04 | Phase 2469 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Dec 8, 2025actual | Apr 17, 2026ClinicalTrials.gov | Open NCT06525935 ↗ |
| Single and Multiple Ascending Dose Study of AMG 133 in Participants With ObesityNCT04478708 / Amgen | CompletedVerified 2025-11Registry results posted | Phase 1110 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 18, 2022actual | Dec 10, 2025ClinicalTrials.gov | Open NCT04478708 ↗ |
| Study of AMG 133 Administered Subcutaneously in Healthy Japanese and Caucasian ParticipantsNCT05056246 / Amgen | CompletedVerified 2025-01Registry results posted | Phase 134 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Apr 8, 2022actual | Feb 25, 2025ClinicalTrials.gov | Open NCT05056246 ↗ |
| Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes MellitusNCT05669599 / Amgen | CompletedVerified 2026-01 | Phase 2592 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Oct 8, 2024actual | Jan 20, 2026ClinicalTrials.gov | Open NCT05669599 ↗ |
| A Study to Evaluate AMG 133 Administered Subcutaneously in Participants With Overweight or ObesityNCT06976372 / Amgen | CompletedVerified 2025-10 | Phase 1120 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Dec 27, 2024actual | Oct 8, 2025ClinicalTrials.gov | Open NCT06976372 ↗ |
| Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) PresentationsNCT07226778 / Amgen | CompletedVerified 2026-06 | Phase 1348 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | May 28, 2026actual | Jun 17, 2026ClinicalTrials.gov | Open NCT07226778 ↗ |
| A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or ObesityNCT07310563 / Amgen | CompletedVerified 2025-12 | Phase 159 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | May 9, 2025actual | Dec 30, 2025ClinicalTrials.gov | Open NCT07310563 ↗ |
| A Trial to Compare the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous PresentationsNCT07313761 / Amgen | CompletedVerified 2026-07 | Phase 1349 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 26, 2026actual | Jul 16, 2026ClinicalTrials.gov | Open NCT07313761 ↗ |
| A Study to Evaluate AMG 133 in Participants With Varying Degrees of Hepatic Impairment or Normal Hepatic FunctionNCT07428525 / Amgen | CompletedVerified 2026-03 | Phase 136 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Feb 26, 2026actual | Mar 11, 2026ClinicalTrials.gov | Open NCT07428525 ↗ |
| The Effect of AMG 133 on Gastric EmptyingNCT07429032 / Amgen | CompletedVerified 2025-12 | Phase 157 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 26, 2025actual | Feb 24, 2026ClinicalTrials.gov | Open NCT07429032 ↗ |
| A Trial to Assess the Effect of Kidney Impairment on How AMG 133 is Absorbed, Broken Down, and Eliminated by the BodyNCT07429045 / Amgen | CompletedVerified 2025-12 | Phase 144 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 21, 2025actual | Feb 24, 2026ClinicalTrials.gov | Open NCT07429045 ↗ |
| A Trial to Assess Bioavailability of AMG 133 in Participants With Overweight or ObesityNCT07717814 / Amgen | CompletedVerified 2026-07 | Phase 1154 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | May 22, 2025actual | Jul 21, 2026ClinicalTrials.gov | Open NCT07717814 ↗ |
| A Study of LY3305677 in Participants With Obesity Or OverweightNCT05623839 / Eli Lilly and Company | CompletedVerified 2023-07 | Phase 132 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 27, 2023actual | Jul 5, 2023ClinicalTrials.gov | Open NCT05623839 ↗ |
| A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or OverweightNCT06124807 / Eli Lilly and Company | CompletedVerified 2026-03Registry results posted | Phase 2179 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jan 22, 2025actual | Apr 21, 2026ClinicalTrials.gov | Open NCT06124807 ↗ |
| A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use DisorderNCT06817356 / Eli Lilly and Company | CompletedVerified 2026-07 | Phase 2308 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 19, 2026actual | Jul 16, 2026ClinicalTrials.gov | Open NCT06817356 ↗ |
| ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)NCT05006885 / Altimmune, Inc. | CompletedVerified 2023-07 | Phase 195 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Aug 17, 2022actual | Jul 27, 2023ClinicalTrials.gov | Open NCT05006885 ↗ |
| ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)NCT05134662 / Altimmune, Inc. | CompletedVerified 2025-06 | Phase 155 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Feb 3, 2023actual | Jun 24, 2025ClinicalTrials.gov | Open NCT05134662 ↗ |
| Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)NCT05292911 / Altimmune, Inc. | CompletedVerified 2022-10 | Phase 164 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Oct 31, 2022actual | Jul 27, 2023ClinicalTrials.gov | Open NCT05292911 ↗ |
| Efficacy and Safety of ALT-801 in the Treatment of ObesityNCT05295875 / Altimmune, Inc. | CompletedVerified 2023-11 | Phase 2391 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 28, 2023actual | Nov 29, 2023ClinicalTrials.gov | Open NCT05295875 ↗ |
| IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)NCT05989711 / IMPACT / Altimmune, Inc. | CompletedVerified 2026-05 | Phase 2212 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 25, 2025actual | May 18, 2026ClinicalTrials.gov | Open NCT05989711 ↗ |
| Once-weekly Petrelintide Versus Placebo for Obesity or Overweight With Co-morbiditiesNCT06662539 / ZUPREME / Zealand Pharma | CompletedVerified 2026-03 | Phase 2493 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 30, 2025actual | Mar 23, 2026ClinicalTrials.gov | Open NCT06662539 ↗ |
| A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)NCT04143802 / Eli Lilly and Company | CompletedVerified 2021-01-15 | Phase 172 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Dec 28, 2020actual | Jan 20, 2021ClinicalTrials.gov | Open NCT04143802 ↗ |
| A Study of LY3437943 in Participants With Type 2 DiabetesNCT04867785 / Eli Lilly and Company | CompletedVerified 2023-06Registry results posted | Phase 2281 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 8, 2022actual | Jul 3, 2023ClinicalTrials.gov | Open NCT04867785 ↗ |
| A Study of LY3437943 in Participants Who Have Obesity or Are OverweightNCT04881760 / Eli Lilly and Company | CompletedVerified 2023-08Registry results posted | Phase 2338 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | May 16, 2022actual | Sep 13, 2023ClinicalTrials.gov | Open NCT04881760 ↗ |
| A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese ParticipantsNCT05445232 / Eli Lilly and Company | CompletedVerified 2023-04-01 | Phase 132 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Feb 24, 2023actual | Apr 18, 2023ClinicalTrials.gov | Open NCT05445232 ↗ |
| A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal FunctionNCT05611957 / Eli Lilly and Company | CompletedVerified 2023-09-15 | Phase 129 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 5, 2023actual | Oct 2, 2023ClinicalTrials.gov | Open NCT05611957 ↗ |
| A Study of Carbon-14-Labelled [14C] LY3437943 in Healthy Male ParticipantsNCT05757531 / Eli Lilly and Company | CompletedVerified 2023-07 | Phase 17 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 23, 2023actual | Jul 5, 2023ClinicalTrials.gov | Open NCT05757531 ↗ |
| A Study of LY3437943 in Participants With Impaired and Normal Liver FunctionNCT05916560 / Eli Lilly and Company | CompletedVerified 2025-04 | Phase 143 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Mar 2, 2025actual | Apr 18, 2025ClinicalTrials.gov | Open NCT05916560 ↗ |
| A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or OverweightNCT05929066 / TRIUMPH-1 / Eli Lilly and Company | CompletedVerified 2026-06 | Phase 32,335 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Apr 6, 2026actual | Jun 3, 2026ClinicalTrials.gov | Open NCT05929066 ↗ |
| A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the KneeNCT05931367 / TRIUMPH-4 / Eli Lilly and Company | CompletedVerified 2026-01 | Phase 3445 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 14, 2025actual | Jan 21, 2026ClinicalTrials.gov | Open NCT05931367 ↗ |
| A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 DiabetesNCT05936151 / Eli Lilly and Company | CompletedVerified 2025-11 | Phase 2146 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Oct 1, 2025actual | Nov 25, 2025ClinicalTrials.gov | Open NCT05936151 ↗ |
| A Study of LY3437943 in Healthy Participants With a High Body Mass IndexNCT05959096 / Eli Lilly and Company | CompletedVerified 2024-09 | Phase 185 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 25, 2024actual | Oct 1, 2024ClinicalTrials.gov | Open NCT05959096 ↗ |
| A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection DevicesNCT06003465 / Eli Lilly and Company | CompletedVerified 2024-03 | Phase 157 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Feb 8, 2024actual | Mar 29, 2024ClinicalTrials.gov | Open NCT06003465 ↗ |
| A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or ObeseNCT06039826 / Eli Lilly and Company | CompletedVerified 2024-07 | Phase 146 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jul 11, 2024actual | Jul 26, 2024ClinicalTrials.gov | Open NCT06039826 ↗ |
| A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943NCT06313528 / Eli Lilly and Company | CompletedVerified 2025-09 | Phase 185 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Aug 26, 2025actual | Sep 23, 2025ClinicalTrials.gov | Open NCT06313528 ↗ |
| Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)NCT06354660 / Eli Lilly and Company | CompletedVerified 2026-03 | Phase 3537 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jan 22, 2026actual | Mar 5, 2026ClinicalTrials.gov | Open NCT06354660 ↗ |
| A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.NCT04153929 / Boehringer Ingelheim | CompletedVerified 2022-11Registry results posted | Phase 2413 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Oct 8, 2021actual | Nov 29, 2022ClinicalTrials.gov | Open NCT04153929 ↗ |
| A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose WeightNCT04667377 / Boehringer Ingelheim | CompletedVerified 2023-10Registry results posted | Phase 2387 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Sep 15, 2022actual | Nov 2, 2023ClinicalTrials.gov | Open NCT04667377 ↗ |
| A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)NCT04771273 / Boehringer Ingelheim | CompletedVerified 2024-11Registry results posted | Phase 2295 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 9, 2023actual | Dec 3, 2024ClinicalTrials.gov | Open NCT04771273 ↗ |
| A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906NCT05296733 / Boehringer Ingelheim | CompletedVerified 2024-08 | Phase 182 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Dec 29, 2023actual | Aug 15, 2024ClinicalTrials.gov | Open NCT05296733 ↗ |
| A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightNCT06066515 / SYNCHRONIZE™-1 / Boehringer Ingelheim | CompletedVerified 2026-03 | Phase 3726 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Dec 2, 2025actual | Mar 12, 2026ClinicalTrials.gov | Open NCT06066515 ↗ |
| A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose WeightNCT06066528 / SYNCHRONIZE™-2 / Boehringer Ingelheim | CompletedVerified 2026-06 | Phase 3755 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Dec 12, 2025actual | Jun 24, 2026ClinicalTrials.gov | Open NCT06066528 ↗ |
| A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)NCT06077864 / Boehringer Ingelheim | CompletedVerified 2026-07 | Phase 35,531 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 1, 2026actual | Jul 23, 2026ClinicalTrials.gov | Open NCT06077864 ↗ |
| A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)NCT06309992 / Boehringer Ingelheim | CompletedVerified 2026-04 | Phase 3218 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Oct 9, 2025actual | Apr 30, 2026ClinicalTrials.gov | Open NCT06309992 ↗ |
| VK2735 for Weight Management Phase 2NCT06068946 / VENTURE / Viking Therapeutics, Inc. | CompletedVerified 2024-12 | Phase 2176 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Feb 27, 2024actual | Feb 12, 2025ClinicalTrials.gov | Open NCT06068946 ↗ |
| VK2735 for Weight Management Phase 2 (Venture Oral Dosing)NCT06828055 / Viking Therapeutics, Inc. | CompletedVerified 2025-09 | Phase 2280 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Jun 24, 2025actual | Oct 6, 2025ClinicalTrials.gov | Open NCT06828055 ↗ |
| A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 DiabetesNCT07357740 / Novo Nordisk A/S | WithdrawnVerified 2026-07 | Phase 20 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Aug 25, 2027estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT07357740 ↗ |
| A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body WeightNCT07357766 / Novo Nordisk A/S | WithdrawnVerified 2026-07 | Phase 30 actual | 0 matching recruitingNo city or postal detail is present for the matching registry rows. | Nov 29, 2027estimated | Jul 9, 2026ClinicalTrials.gov | Open NCT07357766 ↗ |
Recruiting location footprint
Country and US state routes.
Counts are site observations across registry records, not unique facilities. The same research center can appear in multiple studies. Open the exact NCT record before treating a location as current.
Clinical trial finder FAQ
Status, location, and enrollment are different fields.
These answers prevent the most common registry-search errors before a reader follows an official source.
Are any Retatrutide clinical trials recruiting?
Yes. This 2026-07-24 snapshot contains 2 Retatrutide registry records with an overall Recruiting status and 450 listed sites individually marked Recruiting. Overall status does not mean every site is open, and neither status establishes eligibility or enrollment. Open the exact NCT record and verify the individual location before contacting a study team.
How do I find a peptide clinical trial near me?
Enter a city or postal code, optionally add a country or US state, and then open the exact ClinicalTrials.gov record. This finder retains location rows individually marked Recruiting but omits facility and personal contact fields. Confirm current recruitment, eligibility, official contact route, and travel requirements on the registry. Peptide Local does not enroll participants.
Does Recruiting mean I can join the trial?
No. Recruiting is a registry status, not an eligibility decision or appointment. A study can be recruiting overall while some listed locations are not yet recruiting, active but closed, completed, suspended, or missing a current site status. The study team applies the protocol's eligibility and consent process.
Are the drugs in this clinical trial finder FDA approved?
A ClinicalTrials.gov record is not FDA approval. The finder covers investigational programs and can also include studies involving components or comparators with separate regulatory histories. Approval must be verified on the exact FDA label or regulator record, not inferred from a phase, sponsor, trial result, or recruiting status.
Why do only some registry records show posted results?
11 of 268 records in this snapshot expose a ClinicalTrials.gov results module. A record without posted registry results can still have a publication or sponsor announcement elsewhere, while a posted module still requires careful interpretation. Results availability is not a quality rank.
How current is the peptide clinical trial data?
The registry data timestamp is July 24, 2026 at 9:00 AM UTC. The refresh workflow searches exact intervention names and aliases, deduplicates by NCT ID, preserves multi-program studies, and stores overall and individual-site status separately. Registry fields can change after that timestamp, so the direct source remains authoritative for enrollment decisions.
Evidence boundary
A registry finder, not an enrollment service.
A dated transformation of ClinicalTrials.gov intervention-search records for thirteen named Peptide Local pipeline programs. Study sponsors or investigators submit and maintain registry records. Overall status, individual-site status, enrollment, locations, completion dates, and results availability can change. Recruiting status does not establish eligibility, enrollment, treatment access, regulatory approval, routine availability, or a favorable benefit-risk conclusion.
Peptide Local omits personal contact details and does not screen participants, recommend a protocol, interpret eligibility, arrange treatment, or authenticate commercial products that reuse an investigational program's name.
Read the official API documentation ↗Understand evidence categories →